John Zajecka to Placebos
This is a "connection" page, showing publications John Zajecka has written about Placebos.
Connection Strength
0.222
-
Hypericum extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and placebo. Int J Neuropsychopharmacol. 2005 Jun; 8(2):215-21.
Score: 0.058
-
SNRIs in the management of acute major depressive disorder. J Clin Psychiatry. 2004; 65 Suppl 17:11-8.
Score: 0.056
-
Changes in adverse events reported by patients during 6 months of fluoxetine therapy. J Clin Psychiatry. 1999 Jun; 60(6):389-94.
Score: 0.040
-
The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings. J Clin Psychiatry. 1996; 57 Suppl 2:10-4.
Score: 0.032
-
High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. J Clin Psychiatry. 2006 Jan; 67(1):15-22.
Score: 0.016
-
Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry. 1999 Aug; 156(8):1170-6.
Score: 0.010
-
Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am J Psychiatry. 1998 Sep; 155(9):1247-53.
Score: 0.010